Neutropenia
Welcome,         Profile    Billing    Logout  
 413 Companies   276 Products   276 Products   144 Mechanisms of Action   556 Trials   44796 News 


«12...89101112131415161718...627628»
  • ||||||||||  levofloxacin / Generic mfg., azithromycin / Generic mfg.
    An Unexpected Start: Decoding the Mystery of a Newborn's Severe Respiratory Failure (Area B, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P225) -  Feb 24, 2025 - Abstract #ATS2025ATS_3359;    
    ECMO should be considered on an individual basis in neonates with refractory ARDS/shock, and may facilitate accelerated diagnosis and treatment. Water management programs can reduce the risk for Legionella growing and spreading within water systems and devices.
  • ||||||||||  Emphysematous Gastritis and Thyphilitis Associated With Klebsiella Pneumonia (Area J, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1117) -  Feb 24, 2025 - Abstract #ATS2025ATS_2314;    
    Emphysematous gastritis and thyphilitis are rare but life threatening entities, with non specific symptomatology. Therefore, we would like to raise awareness by reporting this case report, emphysematous gastritis and thyphilitis, can be considered in differential diagnosis with immunocompromised patients with vague abdominal symptoms.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Filgrastim-Associated Acute Respiratory Distress Syndrome (Area H, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P992) -  Feb 24, 2025 - Abstract #ATS2025ATS_1848;    
    Empiric treatment for hospital-acquired pneumonia (HAP) was also initiated with meropenem and doxycycline... Clinicians should be vigilant for signs of ARDS in patients receiving filgrastim, especially during periods of rapid neutrophil recovery, and consider early intervention strategies to mitigate potential respiratory complications
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    Secukinumab Associated Eosinophilic Pleural Effusion (Area H, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P972) -  Feb 24, 2025 - Abstract #ATS2025ATS_1828;    
    We share this case to help expand upon the knowledge base of side effects associated with secukinumab. To our knowledge this is the second case reported of eosinophilic effusion associated with secukinumab.
  • ||||||||||  ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., apixaban / Generic mfg.
    Synovial Sarcoma Mets to Lung Presenting as PE (Area K, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1316) -  Feb 24, 2025 - Abstract #ATS2025ATS_1543;    
    Sending PE biopsies to pathology is not standard, which may delay diagnosis. Therefore, a high index of suspicion for metastatic disease is important for patients with synovial sarcoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    PET-Avid Solid Nodule: An Atypical Case of Organizing Pneumonia (Area K, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1289) -  Feb 24, 2025 - Abstract #ATS2025ATS_1500;    
    This report highlights a case of organizing pneumonia, likely secondary to pembrolizumab, that presented as a PET-avid nodule in a patient undergoing evaluation for bone marrow transplantation (BMT)...It can also be located adjacent to infection or malignancy and as such a multidisciplinary communication with pathology was essential to confirm the sample was representative of the entire lesion. This case highlights the importance to differentiate OP from infection or malignancy to avoid delays in critical treatments like bone marrow transplants.
  • ||||||||||  Clinical Utility of Bronchoalveolar Lavage in Oncology Patients at a Pediatric Hospital in Bogota, Colombia (Area E, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P600) -  Feb 24, 2025 - Abstract #ATS2025ATS_926;    
    This case highlights the importance to differentiate OP from infection or malignancy to avoid delays in critical treatments like bone marrow transplants. Bronchoalveolar lavage proved valuable in the diagnostic approach and in guiding antimicrobial therapy for a substantial proportion of pediatric oncology patients, highlighting its role as a safe and effective tool in this population.
  • ||||||||||  Trial completion, Trial completion date:  Oncology Care at Home for BMT and CAR-T (clinicaltrials.gov) -  Feb 21, 2025   
    P=N/A,  N=11, Completed, 
    SSC failed to guide the choice of antibiotics for FN in children with acute leukemia. Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Dec 2024
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Fatal Neutropenia Sepsis Following Acute Methotrexate Toxicity. (Pubmed Central) -  Feb 21, 2025   
    By day 7, his blood counts and symptoms improved, and he was discharged on day 12. This case underscores the importance of patient education on proper MTX dosing to prevent life-threatening complications, particularly in high-risk populations such as the elderly and those with CKD.
  • ||||||||||  Journal:  Post-COVID-19 Neutropenia in an Infant With Thalassemia Minor: Case Report. (Pubmed Central) -  Feb 21, 2025   
    Given the potential for serious clinical implications, including increased susceptibility to infections, it is crucial to effectively identify and manage neutropenia in this vulnerable population. Further research is necessary to elucidate the underlying mechanisms and optimize treatment strategies for COVID-19-related hematological complications in infants.
  • ||||||||||  Journal:  Natural History of Chapare Virus Infection in Strain 13 Guinea Pigs. (Pubmed Central) -  Feb 21, 2025   
    Animals challenged with CHAPV had progressive weight loss, lymphocytopenia, neutropenia, thrombocytopenia, hepatitis, vascular leakage, and gastrointestinal hemorrhage, resulting in uniform lethality between 7- and 16-days following challenge. This work lays the foundation for development of a small animal model of CHAPV infection.
  • ||||||||||  Journal:  Treatment of Post-COVID-19 Pulmonary Aspergilloma: Insights from a Clinical Case. (Pubmed Central) -  Feb 21, 2025   
    CONCLUSIONS Aspergillus infection should be considered in COVID-19 survivors with pulmonary symptoms. Minimally invasive robotic lobectomy is a feasible option for high-risk patients with post-COVID-19 aspergilloma and hemoptysis who are resistant to medical treatment.
  • ||||||||||  ethambutol / Generic mfg.
    Journal:  Scrofuloderma: report of two cases. (Pubmed Central) -  Feb 20, 2025   
    Histopathological features, though suggestive, are not pathognomonic, contributing to diagnostic delays. Increased awareness among dermatologists can lead to earlier diagnosis and better outcomes.
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Clinical, Journal, IO biomarker:  Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (Pubmed Central) -  Feb 20, 2025   
    P3
    Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.).
  • ||||||||||  Retrospective data, Journal, Polymerase Chain Reaction:  Utility of Mucorales PCR to diagnose Rhizomucor infections in neutropenic patients. (Pubmed Central) -  Feb 20, 2025   
    Our study reveals the changing epidemiology of mucormycosis in our center with the use of Mucorales PCR and underlines the importance of the genus Rhizomucor especially in neutropenic patients. This highlights the benefits using Mucorales PCR in clinical practice for mucormycosis diagnosis in high-risk patients, and the need to include it in diagnostic criteria.
  • ||||||||||  Clinical, Journal:  A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated Mucormycosis. (Pubmed Central) -  Feb 20, 2025   
    Timely diagnosis and intervention are essential to prevent severe complications, such as cavernous sinus involvement and bone destruction. These findings emphasize the need for tailored management strategies for CAM in the context of COVID-19, with particular attention to these risk factors.
  • ||||||||||  carboplatin / Generic mfg.
    Observational data, Retrospective data, Journal:  First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis. (Pubmed Central) -  Feb 19, 2025   
    When it is necessary to consider the accessibility of antibody-drug conjugates and the economics of patients, carboplatin-based chemotherapy may be provided to HER2-low patients as a more convenient, cost-effective and efficient option on the front line. Forecasting the efficacy and prognosis via inflammatory index such as NLR before the commencement of the treatment could enhance the precision and efficiency of carboplatin-based regimens.
  • ||||||||||  docetaxel / Generic mfg.
    Journal:  Docetaxel-conjugated bile acid-derived nanomicelles can inhibit tumour progression with reduced toxicity. (Pubmed Central) -  Feb 19, 2025   
    DTX-NMs showed significantly better tolerability and enhanced therapeutic efficacy (survival) compared to DTX alone. This improved tolerability, combined with the maintained therapeutic efficacy of DTX-NMs against murine cancer models, suggests that this hybrid scaffold could offer a more viable and safer option for cancer treatment.
  • ||||||||||  oxaliplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Retrospective data, Journal, Checkpoint inhibition:  Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study. (Pubmed Central) -  Feb 19, 2025   
    The treatment protocol combined ICIs, anti-angiogenic therapy (specifically apatinib), and chemotherapy (S-1 with oxaliplatin)...Only one patient experienced a grade 4 TRAE (immune-related hepatitis), while the most common grade 3 TRAEs included thrombocytopenia, elevated aminotransferase levels, and neutropenia. The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile.
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Retrospective data, Journal:  Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis. (Pubmed Central) -  Feb 19, 2025   
    The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile. Through a literature analysis, it reveals that UPA offers significant therapeutic benefits to AS patients with a relatively high safety profile.
  • ||||||||||  docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    P4 data, Journal:  Toxicity spectrum of taxanes: A safety analysis from pre-marketing to post-marketing. (Pubmed Central) -  Feb 17, 2025   
    The safety of nab-paclitaxel was beyond expectation and unusual signals of alopecia and depression of docetaxel need to be paid attention to. Results of clinical trials and FAERS indicated consistency between premarket and postmarket studies.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis. (Pubmed Central) -  Feb 16, 2025   
    Fifty-four days after the last rituximab administration, the patient was hospitalized for febrile neutropenia due to R-LON, which improved with granulocyte colony-stimulating factor and antibiotics. Although R-LON may resolve spontaneously and remain unnoticed, it can cause severe infections in the elderly and patients with renal failure.